Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

Discover the ultimate roadmap to mastering machine learning skills in 2025. Learn Python, deep learning, and more to boost ...

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Vertex VERX shares rallied 5% in the last trading session to close at $36.21. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session.

Vertex Pharmaceuticals secured European approval for Alyftrek, reinforcing its dominance in cystic fibrosis treatment as ...

While NICE recommended the drug for patients with at least one F508del mutation, Vertex struck a reimbursement deal with NHS England for a broader population.

The raw data generated by simulation codes on supercomputers can be so large that it requires data reduction methods to allow scientists to understand it. Physics-based reductions are often used, for ...